Study summary
Olaparib after treatment helped people with inherited BRCA mutations live longer
89.8%alive at 4 years, vs 86.4% with placebo
What was tested
One year of olaparib, a PARP inhibitor pill, or placebo after standard treatment for high-risk HER2-negative early breast cancer in people with inherited BRCA1 or BRCA2 mutations.
What they found
- 4-year overall survival was 89.8% vs 86.4%.
- Invasive disease-free survival was 82.7% vs 75.4%.
What it means
Genetic testing for BRCA is now standard in TNBC because it opens this option.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.